As more and more companies operating in the pharmaceutical space are moving into cosmetics, the temptation is to think that life will be much easier from a regulatory and compliance perspective. However, while it is true that pharmaceuticals are more heavily regulated, this does not mean that cosmetics developers can rest on their laurels.
The subtle lines between making marketing claims about cosmetics that are deemed allowable and those crossing the line into drug products can often be blurred. The wrong claims can cause a cosmetic product to be misbranded attracting unwanted attention from the US Food and Drug Administration.
In this CPhI podcast with EAS independent advisor, John Bailey, Ph.D. and independent consultant, Catherine Bailey, we take a look at the various common compliance issues that can arise when jumping the boundary from drugs to cosmetics.
Posted in Cosmetics.